Literature DB >> 19765944

Salvia divinorum: exposures reported to a statewide poison control system over 10 years.

Rais Vohra1, Andrew Seefeld, F Lee Cantrell, Richard F Clark.   

Abstract

BACKGROUND: Salvia divinorum, a hallucinogenic herb, has in recent years become popular among teenagers and young adults. Salvia is presently marketed as a "legal" alternative to other drugs of abuse, but little is known about the clinical toxicity of this substance.
OBJECTIVES: The purpose of this study is to describe the clinical and demographic features of this emerging substance of recreational abuse using data obtained from the records of a poison control center.
METHODS: We performed retrospective review of exposures to the herbal hallucinogen Salvia divinorum as reported to the California Poison Control System (CPCS) over the last 10 years. Demographic and clinical data were collected and compiled from the computerized records of the CPCS for the search terms "salvia" and "sage."
RESULTS: There were 37 exposures to S. divinorum and 96 exposures to non-hallucinogenic Salvia species. Eighteen (49%) of the exposures were to S. divinorum alone. Intentional Salvia exposures resulted in a variety of neurologic, cardiovascular, and gastrointestinal effects. Notably, the use of concomitant substances of abuse was associated with a high rate of complications and psychomotor disturbances.
CONCLUSIONS: Intentional use of S. divinorum, whether alone or in combination with alcoholic beverages and other drugs, causes neurologic, cardiovascular, and gastrointestinal effects. This poison-center-based review helps to characterize the clinical toxicity of S. divinorum, but more clinical and pharmacologic research is warranted for this rapidly emerging substance of abuse.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19765944     DOI: 10.1016/j.jemermed.2009.05.019

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  8 in total

1.  Use of Salvia divinorum in a nationally representative sample.

Authors:  Brian E Perron; Brian K Ahmedani; Michael G Vaughn; Joseph E Glass; Arnelyn Abdon; Li-Tzy Wu
Journal:  Am J Drug Alcohol Abuse       Date:  2011-08-11       Impact factor: 3.829

Review 2.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

3.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

4.  Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Authors:  Matthew W Johnson; Katherine A MacLean; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2010-12-04       Impact factor: 4.492

5.  Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers.

Authors:  Li-Tzy Wu; George E Woody; Chongming Yang; Jih-Heng Li; Dan G Blazer
Journal:  Subst Abuse Rehabil       Date:  2011-04

6.  A Report of Nausea and Vomiting with Discontinuation of Chronic Use of Salvia divinorum.

Authors:  C R Travis; G A Ray; K F Marlowe
Journal:  Case Rep Med       Date:  2012-05-07

Review 7.  When good times go bad: managing 'legal high' complications in the emergency department.

Authors:  Charles R Caffrey; Patrick M Lank
Journal:  Open Access Emerg Med       Date:  2017-12-20

Review 8.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.